{
    "key_points": [
        "The FDA and CDC have lifted the recommended pause on the use of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S. after a safety review.",
        "The pause was initially recommended due to six reports of a rare and severe type of blood clot following administration of the vaccine.",
        "Medical and scientific teams reviewed the data, assessed risks, and conducted outreach to healthcare providers during the pause.",
        "The FDA and CDC concluded the vaccine's benefits outweigh the risks for individuals 18 years of age and older.",
        "Data suggest the chance of thrombosis-thrombocytopenia syndrome (TTS) occurring is very low.",
        "Healthcare providers and recipients are urged to review revised fact sheets that include information about the risk of TTS.",
        "The CDC's Advisory Committee on Immunization Practices (ACIP) has reviewed the latest data on TTS.",
        "Janet Woodcock, M.D., Acting FDA Commissioner, emphasized safety as a top priority and the extensive monitoring systems in place.",
        "CDC Director Dr. Rochelle P. Walensky highlighted the effectiveness of vaccine safety systems and encouraged people to consult healthcare providers with questions.",
        "A total of 15 cases of TTS have been reported to VAERS, all in women aged between 18 and 59 years."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Dr. Rochelle P. Walensky (CDC Director)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}